# PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy

> **NCT02805166** · PHASE4 · COMPLETED · sponsor: **CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.** · enrollment: 420 (actual)

## Conditions studied

- Malignant Solid Tumors

## Interventions

- **DRUG:** PEG-rhG-CSF

## Key facts

- **NCT ID:** NCT02805166
- **Lead sponsor:** CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-04
- **Primary completion:** 2016-02
- **Final completion:** 2016-02
- **Target enrollment:** 420 (ACTUAL)
- **Last updated:** 2016-06-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02805166

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02805166, "PEG-rhG-CSF in Patients With Malignant Solid Tumors Receiving Chemotherapy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02805166. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*